Methylenedioxybenzylamphetamine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Methylenedioxybenzylamphetamine
MDBZ.png
Names
IUPAC name
1-(1,3-benzodioxol-5-yl)-N-benzylpropan-2-amine
Identifiers
3D model (JSmol)
UNII
Properties
C17H19NO2
Molar mass 269.343 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
No verify (what is YesYNo ?)
Infobox references

MDBZ, or 3,4-methylenedioxy-N-benzylamphetamine, is a lesser-known psychedelic drug. It is the N-benzyl derivative of MDA. MDBZ was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown. MDBZ produces few to no effects. Very few data exist about the pharmacological properties, metabolism, and toxicity of MDBZ.

In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to 3,4-methylenedioxy-N-benzylamphetamine.[1]

Legality[edit]

United Kingdom[edit]

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also[edit]

References[edit]

External links[edit]